GlassScriptPrepare for your visit
Neeharika Repaka
Endocrinology, Diabetes & Metabolism · Reston, VA · NPI 1235427592
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$5,979.27
in general payments reported to CMS, 2019-2025 · $1,065 in 2025
The $1,065 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Who reported paying
General payments only, top 6 by amount.
- Lilly USA, LLC $1,052.03
- Novo Nordisk INC $643.70
- Corcept Therapeutics $450.73
- Abbvie INC. $431.79
- Amneal Pharmaceuticals LLC $329.53
- Insulet Corporation $283.20
Drugs and devices associated with these payments
Jardiance Ilet Bionic Pancreas Mounjaro Zepbound Unithroid Korlym Minimed 780g Omnipod Strensiq Wegovy Recorlev Ozempic
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Neeharika Repaka listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/569149/neeharika-repaka